Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The antinociceptive effects of endomorphin-1 and endomorphin-2 in diabeticmice
Autore:
Kamei, J; Zushida, K; Ohsawa, M; Nagase, H;
Indirizzi:
Hoshi Univ, Fac Pharmaceut Sci, Dept Pathophysiol & Therapeut, Shinagawa Ku, Tokyo 1428501, Japan Hoshi Univ Tokyo Japan 1428501 apeut, Shinagawa Ku, Tokyo 1428501, Japan Toray Ind, Basic Res Labs, Kamakura, Kanagawa 2488555, Japan Toray Ind Kamakura Kanagawa Japan 2488555 makura, Kanagawa 2488555, Japan
Titolo Testata:
EUROPEAN JOURNAL OF PHARMACOLOGY
fascicolo: 1-2, volume: 391, anno: 2000,
pagine: 91 - 96
SICI:
0014-2999(20000310)391:1-2<91:TAEOEA>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
DELTA-OPIOID RECEPTORS; ANALGESIA; MORPHINE; AGONIST; HEROIN; MOUSE; BRAIN;
Keywords:
endomorphin-1; endomorphin-2; diabetes; antinociception; delta-opioid receptor; mu-opioid receptor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Kamei, J Hoshi Univ, Fac Pharmaceut Sci, Dept Pathophysiol & Therapeut, Shinagawa Ku, 4-41 Ebara 2 Chome, Tokyo 1428501, Japan Hoshi Univ 4-41 Ebara 2 Chome Tokyo Japan 1428501 1428501, Japan
Citazione:
J. Kamei et al., "The antinociceptive effects of endomorphin-1 and endomorphin-2 in diabeticmice", EUR J PHARM, 391(1-2), 2000, pp. 91-96

Abstract

The antinociceptive effects of endomorphin-1 and endomorphin-2, endogenousmu-opioid receptor agonists, were examined using the tail-flick test in non-diabetic and diabetic mice. Endomorphin-1, at doses of 1 to 10 mu g, i.c.v., and endomorphin-2, at doses of 3 to 30 mu g, i.c.v., each dose dependently inhibited the tail-flick response in both non-diabetic and diabetic mice. There was no significant difference between the antinociceptive effects of endomorphin-1 in non-diabetic mice and diabetic mice. The antinociceptive effect of endomorphin-2 was greater in non-diabetic mice than in diabeticmice. In non-diabetic mice, the antinociceptive effects of endomorphin-1 and endomorphin-2 were significantly reduced by beta-funaltrexanline, a mu-opioid receptor antagonist, and naloxonazine, a selective mu(1)-opioid receptor antagonist, but not by naltrindole, a delta-opioid receptor antagonist,or nor-binaltorphimine, a kappa-opioid receptor antagonist. In diabetic mice, the antinociceptive effect of endomorphin-3 was significantly reduced by beta-funaltrexamine and naloxonazine. However, these mu-opioid receptor antagonists had no significant effect on the antinociceptive effect of endomorphin-1 in diabetic mice. The antinociception induced by endomorphin-1 in diabetic mice was significantly reduced by naltrindole and 7-benzylidenenaltrexon, a selective delta(1)-opioid receptor antagonist, administered i.c.v. However. nor-binaltorphimine had no significant effect on the antinociceptive effects of endomorphin-1 and endomorphin-2 in diabetic mice. These results indicate that the antinociceptive effects of endomorphin-1 and endomorphin-2, in non-diabetic mice an mediated through the activation of mu(1)-opioid receptors, whereas in diabetic mice, endomorphin-1 and endomorphin-2 may produce antinociception through different actions at delta(1)- and mu(1)-opioid receptors, respectively. (C) 2000 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 09:14:25